Human papillomavirus in cervical cancer screening: Important role as biomarker

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 4, 2008, Pages 810-817

  Boulet, Gaëlle A V ^a   Horvath, Caroline A J ^a   Berghmans, Sarah ^b   Bogers, Johannes ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b Laboratory for Clinical Pathology (Labo Lokeren Campus RIATOL)   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; RNA;

CANCER GRADING; CANCER SCREENING; CARCINOGENESIS; CAUSAL ATTRIBUTION; DEVELOPING COUNTRY; DISEASE MARKER; FOLLOW UP; GENE EXPRESSION; GENOTYPE; HUMAN; PAPANICOLAOU TEST; PRIORITY JOURNAL; SHORT SURVEY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; VIRUS LOAD; WART VIRUS;

BIOLOGICAL MARKERS; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; GENOME, VIRAL; HUMANS; MASS SCREENING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RNA, VIRAL; UTERINE CERVICAL NEOPLASMS;

EID: 42149149840     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-2865     Document Type: Short Survey

References (105)

1. Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006;24:S11-25.
2. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007;7:11-22.
3. Cannistra SA, Niloff JM. Cancer of the uterine cervix. N Eng J Med 1996;334:1030-8.
4. Stanley MA. Prognostic factors and new therapeutic approaches to cervical cancer. Virus Res 2002;89:241-8.
5. Smith JFH. Bethesda 2001. Cytopathology 2002;13:4-10.
6. Baldwin P, Laskey R, Coleman N. Translational approaches to improving cervical screening. Nat Rev Cancer 2003;3:217-26.
7. Koss LG. The Papanicolaou test for cervical cancer detection. JAMA 1989;261:737-43.
8. Bekkers RLM, Massuger LFAG, Bulten J, et al. Epidemiological and clinical aspects of human papillomavirus detection in the prevention of cervical cancer. Rev Med Virol 2004;14:95-105.
9. Michalas SP. The Pap test: George N. Papanicolaou (1883-1962) A screening test for the prevention of cancer of uterine cervix. Eur J Obstet Gynecol Reprod Biol 2000;90:135-8.
10. Kitchener HC, Castle PE, Cox TJ. Chapter 7: achievements and limitations of cervical cytology screening. Vaccine 2006;24S3:S3/63-S3/70.
11. Wright TC. Cervical cancer screening in the 21st century: is it time to retire the PAP smear? Clin Obst Gynecol 2007;50:313-23.
12. Lie AK, Risberg B, Borge B, et al. DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecol Oncol 2005;97:908-15.
13. Arbyn M, Herbert A, Schenck P, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology. Cytopathology 2007;18:133-9.
14. IARC Working Group, on the Evaluation of Cancer Prevention Strategies. Cervix Cancer Screening, volume 10. Lyon: IARC Press; 2005.
15. Franco EL, Ferenczy A. Cervical cancer screening following the implementation of prophylactic human papillomavirus vaccination. Future Oncol 2007;3:319-27.
16. Davies P, Arbyn M, Dillner J, Kitchener HC, et al. A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening. Int J Cancer 2005;118:794-6.
17. Commission of the European Communities. Proposal for a council recommendation on cancer screening. 2003/0093 (CNS). Brussels, 5 May, 2003.
18. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
19. Bosch FX, Lorincz A, Muñoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
20. Hebner CM, Laimins LA. Human papillomavirus: basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol 2006;16:83-97.
21. Fehrmann F, Laimins LA. Human papillomaviruses targeting differentiating epithelial cells for malignant transformation. Oncogene 2003;22:5201-7.
22. Boulet G, Horvath C, Vanden Broeck D, et al. Human papillomavirus: E6 and E7 oncogenes. Int J Biochem Cell Biol 2007;39:2006-11.
23. Molijn A, Kleter B, Quint W, et al. Molecular diagnosis of human papillomavirus (HPV) infections. J Clin Virol 2005;32S:S43-51.
24. Villa L, Denny L. Methods for detection of HPV infection and its clinical utility. Int J Gynecol Obstet 2006;94:S71-80.
25. Arbyn M, Sasieni P, Meijer CJLM, et al. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006;24S3:S3/78-S3/89.
26. Koliopoulos G, Arbyn M, Martin-Hirsch P, et al. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol 2007;104:232-6.
27. ASCUS-LSIL Triage Study Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous lesions, follow-up of women treated for high-grade CIN. Am J Obstet Gynecol 2003;188:1383-92.
28. Arbyn M, Buntinx F, Van Ranst M, et al. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004;96:280-93.
29. Paraskevaidis E, Arbyn M, Sotiriadis A, et al. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev 2004;30:205-11.
30. Zielinski GD, Bais AG, Helmerhorst TJ, et al. HPV testing and monitoring of women after treatment of CIN3: review of the literature and meta-analysis. Obstet Gynecol Surv 2004;59:543-53.
31. Arbyn M, Paraskevaidis E, Martin-Hirsch P, et al. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol 2005;99:7-11.
32. Cuzick J, Beverley E, Ho L, et al. HPV testing in primary screening of older women. Br J Cancer 1999;81:554-8.
33. Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 2000;283:87-93.
34. Clavel C, Masure M, Bory JP, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001;84:1616-23.
35. Cuzick J, Mayrand MH, Ronco G, et al. Chapter 10: new dimensions in cervical cancer screening. Vaccine 2006;24S3:S3/90-S3/97.
36. Manos M, Kinney WK, Hurley LB, et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999;281:1605-10.
37. Wheeler CM. Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing. Nat Clin Pract Oncol 2007;4:224-35.
38. ALTS 2000 & Anonymous. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst 2000;92:397-402.
39. Stoler MH, Castle PE, Solomon D, et al. American Society for Colposcopy and Cervical Pathology: the expanded use of HPV testing in gynaecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol 2007;127:335-7.
40. Peyton CL, Schiffman M, Lörincz AT, et al. Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol 1998;36:3248-54.
41. Vernon SD, Unger ER, Williams D. Comparison of human papillomavirus detection and typing by cycle sequencing, line blotting, and hybrid capture. J Clin Microbiol 2000;38:651-5.
42. Coutlee F, Gravitt P, Kornegay J, et al. Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples. J Clin Microbiol 2002;40:902-7.
43. Clifford G, Franceschi S, Diaz M, et al. Chapter 3: HPV-type distribution in women with and without cervical neoplastic diseases. Vaccine 2006;23S3:S3/26-S3/24.
44. Manos MM, Ting MY, Wright DK, et al. The use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells 1989;7:209-14.
45. Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235-40.
46. Qu W, Jiang G, Cruz Y, et al. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol 1997;35:1304-10.
47. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000;38:357-61.
48. Castle PE, Schiffman M, Gravitt PE, et al. Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol 2002;68:417-23.
49. Kleter B, van Doorn LJ, ter Schegget J, et al. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol 1998;153:1731-9.
50. Perrons C, Kleter B, Jelley R, et al. Detection and genotyping of human papillomavirus DNA by SPF10 and MY09/11 primers in cervical cells taken form women attending a colposcopy clinic. J Med Virol 2002;67:246-52.
51. Depuydt CE, Boulet GAV, Horvath CAJ, et al. Comparison of MY09/11 consensus PCR and type-specific PCRs in the detection of oncogenic HPV types. JCMM 2007;11:881-91.
52. Van Ham MA, Bakker JM, Harbers GK, et al. Comparison of two commercial assays for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche AMPLICOR HPV test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders. J Clin Microbiol 2005;43:2662-7.
53. Monsonego J, Bohbot JM, Pollini G, et al. Performance of the Roche AMPLICOR human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear. Gynecol Oncol 2005;99:160-8.
54. Clifford GM, Smith JS, Aguado T, et al. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003;89:101-5.
55. Cuschieri KS, Whitley MJ, Cubie HA. Human papillomavirus type specific DNA and RNA persistence-implications for cervical disease progression and monitoring. J Med Virol 2004;73:65-70.
56. Giuliani L, Coletti A, Syrjänen K, Favelli C, Ciotti M. Comparison of DNA sequencing and Roche Linear array in human papillomavirus (HPV) genotyping. Anticancer Res 2006;26:3939-41.
57. Coutlée F, Rouleau D, Petignat P, et al. Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the linear array HPV genotyping test. J Clin Microbiol 2006;44:1998-2006.
58. Kleter B, Van Doorn L, Schrauwen L, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999;37:2508-17.
59. Jiang H, Zhu H, Zhou L, Chen F, Chen Z. Genotyping of human papillomavirus in cervical lesions by L1 consensus PCR and the Luminex xMAP system. J Med Microbiol 2006;55:715-20.
60. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
61. Josefsson AM, Magnusson PK, Ylitalo N, et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 2000;355:2189-93.
62. Dalstein V, Riethmuller D, Pretet JL, et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 2003;106:396-403.
63. Moberg M, Gustavsson I, Wilander E, et al. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer 2005;92:891-4.
64. Moberg M, Gustavsson I, Gyllensten U. Real-time PCR-based system for simultaneous quantification of human papillomavirus types associated with high risk of cervical cancer. J Clin Microbiol 2003;41:3221-8.
65. Depuydt CE, Benoy IH, Bailleul EJ, et al. Improved endocervical sampling and HPV viral load detection by Cervex-Brush Combi. Cytopathology 2006;17:1-8.
66. Gravitt P, Kovacic M, Herrero R, et al. High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int J Cancer 2007;121:2787-93.
67. Jeon S, Lambert PF. Integration of human papillomavirus type 16 DNA into human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc Natl Acad Sci 1995;92:1654-8.
68. Arias-Pulido H, Peyton C, Joste N, Vargas H, Wheeler C. Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer. J Clin Microbiol 2006;44:1755-62.
69. Tonon SA, Picconi MA, Bos PD, et al. Physical status of the E2 human papillomavirus 16 viral gene in cervical preneoplastic and neoplastic lesions. J Clin Virol 2001;21:129-34.
70. Badaracco G, Venuti A, Sedati, et al. HPV16 and HPV18 in genital tumors: significantly different levels of viral integration and correlation to tumor invasiveness. J Med Virol 2002;67:574-82.
71. Alazawi W, Pett M, Strauss S, et al. Genomic imbalances in 70 snap-frozen cervical squamous intraepithelial lesions: associations with lesion grade, state of the HPV16 E2 gene and clinical outcome. Br J Cancer 2004;91:2063-70.
72. Hudelist G, Manavi M, Pischinger KI, et al. Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade. Gynecol Oncol 2004;92:873-80.
73. Andersson S, Safari H, Mints M, et al. Type distribution, viral load and integration status of high-risk human papillomaviruses in prestages of cervical cancer (CIN). Br J Cancer 2005;92:2195-200.
74. Cheung JL, Lo KW, Cheung TH, et al. Viral load, E2 gene disruption status, and lineage of human papillomavirus type 16 infection in cervical neoplasia. J Infect Dis 2006;194:1706-12.
75. Guo M, Sneige N, Silva EG, et al. Distribution and viral load of eight oncogenic types of human papillomavirus (HPV) and HPV 16 integration status in cervical intraepithelial neoplasia and carcinoma. Mod Pathol 2007;20:256-66.
76. Molden T, Kraus I, Karlsen F, et al. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev 2005;14:367-72.
77. Powell N, Smith K, Fiander A. Recovery of human papillomavirus nucleic acids from liquid-based cytology media. J Virol Methods 2006;137:58-62.
78. Horvath CA, Boulet G, Sahebali S, et al. Effects of fixation on RNA integrity in a liquid based cervical cytology setting. J Clin Pathol 2008;61:132-7.
79. Molden T, Kraus I, Skomedal H, et al. PreTect HPV-proofer: real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses. J Virol Methods 2007;142:204-12.
80. Molden T, Kraus I, Karlsen F, et al. Human papillomavirus E6/E7 mRNA expression in women younger than 30 years of age. Gynecol Oncol 2006;100:95-100.
81. Rosini S, Zappacosta R, Di Bonaventura G, et al. Management and triage of women with human papillomavirus infection in follow-up for low-grade cervical disease: association of HPV-DNA and RNA-based methods. Int J Immunopathol Pharmacol 2007;20:341-7.
82. Castle P, Dockter J, Giachetti C, et al. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for the detection of cervical precancer and cancer. Clin Cancer Res 2007;13:2599-605.
83. Wang-Johanning F, Lu DW, Wang Y, et al. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou test using real-time polymerase chain reaction analysis. Cancer 2002;94:2199-210.
84. Sahebali S, Depuydt CE, Segers K, et al. Ki-67 immunocytochemistry in liquid-based cervical cytology: useful as an adjunctive tool? J Clin Pathol 2003;56:681-6.
85. Sahebali S, Depuydt CE, Segers K, et al. P16INK4A as an adjunct marker in liquid-based cervical cytology. Int J Cancer 2004;108:871-6.
86. Kolch W, Mischak H, Pitt AR. The molecular make-up of a tumour: proteomics in cancer research. Clin Sci 2005;108:369-83.
87. Kuramitsu Y, Nakamura K. Proteomic analysis of cancer tissues: shedding light on carcinogenesis and possible biomarkers. Proteomics 2006;6:5650-61.
88. Brusic V, Marina O, Wu CJ, et al. Proteome informatics for cancer research: from molecules to clinic. Proteomics 2007;7:976-91.
89. Cho WCS. Contribution of oncoproteins to cancer biomarker discovery. Mol Cancer 2007;6:1-13.
90. Yim EK, Park JS. Role of proteomics in translational research in cervical cancer. Exp Rev Proteomics 2006;3:21-36.
91. zur Hausen H. Perspectives of contemporary papillomavirus research. Vaccine 2006;24S3:S3/iii-S3/iv.
92. Chan JK, Berek JS. Impact of the human papillomavirus vaccine on cervical cancer. J Clin Oncol 2007;25:2975-82.
93. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
94. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized control trial. Lancet 2004;364:1757-65.
95. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
96. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 2006;367:1247-55.
97. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized control trial. Obstet Gynecol 2006;107:18-27.
98. Koutsky LA, Harper DM. Chapter 13: current findings from prophylactic HPV vaccine trials. Vaccine 2006;24S3:S3/114-S3/121.
99. Muñoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
100. Bryan JT. Developing an HPV vaccine to prevent cervical cancer and genital warts. Vaccine 2007;25:3001-6.
101. Dillner J, Arbyn M, Dillner L. Translational mini-review series on vaccines: monitoring of human papillomavirus vaccination. Clin Exp Immunol 2007;148:199-207.
102. Adams M, Jasani B, Fiander A. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening. Vaccine 2007;25:3007-13.
103. Denny L, Michael Q, Sankaranarayanan R. Chapter 8: screening for cervical cancer indeveloping countries.Vaccine 2006;2453:S3/71-S3/77.
104. Franco EL, Cuzick J, Hildesheim A, et al. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 2006;24S3:S3/171-S3/177.
105. Arbyn M, Van Oyen H. Analysis of individual health insurance data pertaining to Pap smears, colposcopies, biopsies and surgery on the uterine cervix (Belgium, 1996-2000). Brussels: Scientific Institute of Public Health; 2004.